PI3K Genetic Alteration Cell Panel (ATCC® TCP-1028)

Organism: Homo sapiens, human  / 

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Components ATCC CCL-225 HCT-15
ATCC CCL-237 SW948
ATCC HTB-121 BT-483
Applications This panel is useful for PI3K pathway research and for anti-cancer drug discovery.
Biosafety Level 2 [Cells contain Parainfluenza virus type 5]

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.


The Phosphoinositide 3‑kinases (PI3Ks) family of enzymes is integral to several signaling pathways that mediate cell proliferation, survival, migration and vesicular trafficking. Member of the PI3K family are frequently mutated or altered in human cancers. For example, gain-of-function mutations in p110α (encoded by the PI3KCA gene) are observed in a variety of common cancers; and, these mutations are exclusively clustered in one of two hotspot regions, (i.e., exon 9 and 20), which correspond to either the helical or kinase domains of the protein (e.g., E545K and H1047R).

The PI3K Genetic Alteration Cell Panel (ATCC TCP-1028) is composed of ten human tumor cell lines from common cancer types that carry hotspot mutations within the PIK3CA gene. The PI3KCA status of each cell line has been sequenced and validated by ATCC. This panel is useful for PI3K pathway research and for anti-cancer drug discovery.

Product Format frozen
Storage Conditions LN vapor (less than -130°C) only
Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • For-profit customers must obtain a research use license agreement from the Contributor prior to shipment.
  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

Unless the Purchaser has a separate license agreement with The University of Texas M. D. Anderson Cancer Center (“Institution”), the ATCC Material is subject to the following restrictions:

  1. The ATCC Material (and any Modifications, Unmodified Derivatives and/or Progeny thereof) may not be used (1) for commercial purposes or Commercial Use by any Purchaser, or (2) by for-profit or commercial entities for any purpose;
  2. Purchaser may not transfer ATCC Materials, Modifications, Unmodified Derivatives, or Progeny to any for-profit entity or commercial entity; and
  3. Purchaser may not use ATCC Materials (or any Modifications, Unmodified Derivatives and/or Progeny thereof) in connection with any research, collaboration or other activities involving a third party that is a commercial entity or for-profit entity.

The restrictions set forth above are in addition to the restrictions set forth in the ATCC Material Transfer Agreement. Capitalized terms have the meanings set forth in the ATCC Material Transfer Agreement unless otherwise indicated above.

For instructions on how to obtain a license from Institution, please contact John B. Scott, Ph.D. at the Institution Office of Technology Commercialization via email at jscott3@mdanderson.org.